在MGD患者中影响梅博米腺长期变化的因素
Xichen Wan1, Yuqing Wu1, Zimeng Zhai1
1Department of Ophthalmology, Eye, Ear, Nose and Throat Hospital of Fudan University, Shanghai, China.
概括
一年多的梅博米腺功能障碍 (MGD) 治疗显示出有限的改善,只有34.2%的患者康复. 年轻的年龄和更好的角膜光素染色 (CFS) 恢复与改善的梅博米腺 (MG) 功能有关.
科学领域:
- 眼科医生 眼科 眼科
- 干眼疾病研究 干眼疾病研究
- 梅博姆腺功能障碍研究 梅博姆腺功能障碍研究
背景情况:
- 梅博米腺功能障碍 (MGD) 是蒸发性干眼的常见原因.
- 了解MGD的长期进展和恢复因素对于有效的管理至关重要.
- 梅博姆腺脱落显著影响眼睛表面的健康.
研究的目的:
- 调查诊断为MGD的患者的长期临床过程.
- 在MGD患者中确定影响梅博米腺 (MG) 脱落恢复的因素.
- 分析治疗干预措施与MG功能随时间的推移之间的关系.
主要方法:
- 79名MGD患者的回顾性研究,随访时间超过一年.
- 评价角膜光染色 (CFS),撕裂半径高度 (TMH),非侵入性断裂时间 (NIBUT) 和美图.
- 使用自动MG分析仪测量MG面积比 (AR),扭曲度指数 (TI) 和信号指数 (SI).
主要成果:
- 只有34.2%的MGD患者在治疗一年以上后显示出梅博米腺改善.
- 与MG恢复负相关的因素包括年龄较大,女性性别和基线AR.
- 改善的角膜光素染色 (CFS) 和增加的信号指数 (SI) 与MG的改善有关,同时治疗IPL.
结论:
- 长期的MGD治疗产生了适度的改善率,34.2%的人经历了MG增强.
- 较年轻的患者和具有较好的角膜光素染色 (CFS) 恢复的患者显示MG改善的可能性更高.
- 年龄,CFS变化和基线MG区域是MGD患者长期MG变化的关键预测因素.
相关概念视频
01:20Myasthenia Gravis: Overview and Treatment
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
01:22Microbiome of the Eye
The human eye has a specialized microbiota that reflects its unique anatomical and immunological environment. This low-biomass microbial community predominantly colonizes the conjunctiva and eyelid margins, playing a vital role in ocular surface homeostasis and defense. Despite its proximity to the richly colonized facial skin, the ocular surface maintains a distinct microbial profile due to continuous mechanical and biochemical defense mechanisms.The conjunctival surface hosts fewer microbial...
01:22Myasthenia Gravis ll: Pathophysiology
The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...